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• The insulin-like growth factors (IGF-I and IGF-II) play 
important roles in growth and development. They are struc- 
turally homologous to proinsulin and can interact with the 
type I and type II IGF receptors and, to a lesser extent, the 
insulin receptor (1). IGF have potent hypoglycemic activity, 
which is modulated by the presence of specific IGF-binding 
proteins, six of which (IGFBP-1 to IGFBP-6) have been cloned 
to date (2,3). Postnatally, IGF-stimulated growth is merely 
regulated by pituitary-derived growth hormone (GH). How- 
ever, prenatal growth regulation by IGF is GH-independent 
(4). IGF and IGFBP are produced by many tissues and circu- 
late in plasma, suggesting that they act both by endocrine and 
autocrine/paracrine mechanisms (5). In spite of the vast lit- 
erature about IGF, their physiological implications in prena- 
tal and postnatal growth regulation are insufficiently known. 
This is especially true for IGF-II. Therefore, this article will 
dance round a few selected aspects relevant to the biological 
effects of IGF-II in vivo. 
IGF-II IN PHYLOGENY AMD ONTOGENY 
• IGF-like molecules are found in species whose origins 
extend back over 550 million years. A hybrid insulin/IGF 
cDNA has been cloned from the protochordate Amphioxus 
californiensis, an invertebrate from which the vertebrates 
emerged. In the Atlantic hagfish, one of the most primitive 
vertebrates belonging to the group of the agnathans, a proto- 
type IGF molecule has been cloned beside insulin, with a re- 
markable degree of sequence identity to the human IGF. This 
ancestral IGF molecule gave rise to two distinct IGFs in the 
elasmobranchs, a major group of vertebrates that lies between 
agnathans and teleosts on the phylogenetic tree (6). To date 
molecules with obvious sequence identity to either IGF-I or 
IGF-II have been demonstrated in teleosts, amphibians, birds 
and mammals (7). 
IGF-I and IGF-II are polypeptides of 70 and 67 amino acid 
residues, respectively, encoded by separate genes, whose tran- 
scription and mRNA translation are developmentally regu- 
lated (8,9). Both IGF-I and IGF-II are already expressed dur- 
ing preimplantation embryogenesis (10,11). In rodents, IGF- 
II is synthesized primarily during the fetal and neonatal pe- 
riod but disappears from the serum in the early postnatal pe- 
riod. This maybe due to absence in these animals of one of the 
four promoters in the IGF-II gene, which directs "adult spe- 
cific" expression of the IGF-II gene in man as well as in cattle, 
dogs, monkeys, guinea pigs and others (9). In these species, 
IGF-II production continues throughout life, with relatively 
high concentrations of the peptide being found in adult serum 
(1), whereas in the adult rat tissue specific expression can only 
be demonstrated in brain, growth plate cartilage and bone (12- 
14). Most studies regarding a possible physiological role of 
IGF-II in vivo have been performed in rodents, since they are 
much easier to manipulate by transgenesis or gene targeting 
than others. It is wise to keep in mind these differences in 
postnatal IGF-II concentrations before extrapolating data ob- 
tained from rodents to man and other species. 
  
  
  
IGF-II RECEPTORS 
• The type I IGF receptor appears to mediate most physi- 
ological responses of IGF-II on cell growth. This receptor is 
stractually related to the insulin receptor and belongs to the 
class of growth factor receptors with intrinsic tyrosine kinase 
activity (7). IGF-II also binds to the type II IGF receptor which 
is identical to the cation-independent mannose-6-phosphate 
receptor. Its physiological role as a cell surface receptor for 
IGF-II is currently unclear. Ligand binding to this type II re- 
ceptor seems to be coupled to G-protein activation and Ca
2+
- 
influx (15,16). Its main function appears to be targeting of 
lysosomal enzymes (17). 
IGF-II-BINDIMG PROTEINS 
• Like the IGF, their binding proteins are widespread in 
the animal kingdom. Not only do they function as carrier pro- 
teins, but they can inhibit or stimulate IGF-mediated actions. 
However, the precise mechanism by which IGFBPs modulate 
IGF signalling remains speculative (5). IGFBP-1, -3 and -4 
bind IGF-I and IGF-II with approximately equal affinities, 
whereas the others have a higher affinity for IGF-II. IGFBP- 
3, the predominant serum IGFBP, is unique in that it binds to 
an additional 85 kD protein known as the acid-labile subunit 
to form a 150 kD complex that does not cross the vascular 
epithelium thereby increasing the half life of serum IGF (2). 
IGF-II IM PRENATAL AMD POSTNATAL GROWTH 
• IGF-II is a pleiotropic growth factor influencing 
growth, glucose metabolism, organ homeostasis, the immune 
and nervous systems and the fetoplacental unit (18). Exogenous 
IGF-II and IGF-I are important regulators of fetal growth from 
the earliest preimplantation stages of embryonic development 
onwards (19,20). 
Postnatally, systemic administration of recombinant IGF-II 
promotes the growth of normal rats and growth hormone-de- 
ficient rats and mice, although IGF-II is generally less potent 
than IGF-I (21-23). Both IGF-I and IGF-II, alone or in combi- 
nation with growth hormone (GH), show distinct effects on 
growth of the liver in pituitary-deficient Snell dwarf mice (23). 
In animals with high levels of IGF-I and IGF-II, alteration at 
the levels of one IGF results in a reciprocal change at the level 
of the other one (24). Thus, growth will not be altered by treat- 
ing these animals with either IGF-I or IGF-II as has been ob- 
served in guinea pigs (25). 
Although IGF-II is, in general, a poor stimulator of growth, it 
is an important regulator of intermediary metabolism in chick- 
ens (26) and sheep (27). In the latter, coadministration of IGF- 
II completely blocks the anabolic effect of IGF-I (27). Like- 
wise in man, IGF-II influences both lipid and carbohydrate 
metabolism as shown by the induction of sustained insulin 
sensitivity in two patients with insulin resistance and 
hyperlipidemia. In this regard IGF-II may prove to be of ben- 
efit in the treatment of lipodystrophy (28). 
In the normal neonate, colostrum- and milk-derived growth 
factors have great implications for overall growth and devel- 
opment (29,30). IGF-I, and to a lesser extent IGF-II, increase 
milk secretion by direct infusion in the mammary gland in 
goats (31). 
In the immune system, the predominance of IGF-II in the thy- 
mus suggests a role for IGF-II (32). Indeed, transgenic mice 
overexpressing IGF-II under the transcriptional control of the 
H2Kb promoter show increased growth of the thymus due to 
an increase in thymocyte number (33,34). 
IGF-II is produced throughout life in rat brain (12,13) and its 
expression is induced following hypoxic-ischemic injury. 
Whereas IGF-II may modulate the response of glial cells dur- 
ing recovery from cerebral infarction, IGF-I appears to reduce 
the incidence of infarction and thus may act as an neuronal 
survival factor (35). By itself, IGF-II stimulates motor nerve 
regeneration in rats and spontaneous regeneration can be in- 
hibited by anti-IGF-II antiserum (36). Another fimction of IGF- 
II in the central nervous system may be in the control of food 
intake, since intracerebroventricularly injected IGF-II in rats 
results in a decrease in food intake, whereas IGF-I has no ef- 
fect (37). 
New insights for a possible physiological role of IGF-II were 
obtained from studies in transgenic mice overexpressing or 
lacking IGF-II. In IGF-II transgenic mice with elevated se- 
rum IGF-II levels body growth was either decreased (38) or 
not significantly influenced (33,39,40). Overexpression in spe- 
cific organs may result in disproportionate growth as reported 
for the thymus (33), uterus (39), kidneys and testis (40). These 
data indicate distinct local and systemic actions for IGF-II in 
these animals. 
By contrast, mice lacking IGF-II are 60% of the size of their 
wild-type littermates at birth, whereafter growth continues 
parallelly to that of normal mice, suggesting an important role 
in fetal growth. This contrasts with the growth pattern of IGF- 
I knock-out mice. At birth these animals are also 60% of 
normals in size, but they continue to be growth retarded post- 
natally reaching a maximum weight of 25-30% of wild-type 
siblings. Their survival rate is lower compared to IGF-II knock- 
outs. This is indicative for the importance of IGF-I in both 
prenatal and postnatal growth regulation (41). Surprisingly, 
loss of the type II IGF receptor results in fetal overgrowth and 
perinatal lethality. This phenotype is probably caused by an 
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excess of IGF-II because introduction of an IGF-II null allele 
rescues the type II IGF receptor mutant mice (42). This indi- 
cates that expression of this receptor is essential for late em- 
bryonic development and growth regulation. The same is true 
for the type I IGF receptor, inactivation of which leads to 
growth retardation and perinatal lethality (43). Insulin recep- 
tor substrate-1 (ERS-1) is the major substrate both for insulin 
and type I IGF receptors. Mice homozygous for a targeted 
disruption of this gene were born alive but were retarded in 
embryonal and postnatal growth. This suggests the existence 
both of IRS-I-dependent and IRS-I-independent pathways for 
signal transduction of insulin and both IGF-I and IGF-II (44). 
IMPRINTING 
• Both IGF-II and type II IGF receptor are genetically 
imprinted in mice; the paternal allele of the IGF-II gene is 
expressed, whereas of the type II IGF receptor the maternal 
allele is the active copy (41,43). In man, IGF-II is parentally 
imprinted as in mice. The type II IGF receptor is imprinted 
only in a minority of individuals (45). The phenotypic expres- 
sion of gene imprinting is subject to tissue specificity and de- 
velopmental regulation. It has been suggested that imprinting 
may have occurred during evolution because of conflicting 
parental interest in the growth rates of offspring, male gene 
transmission being favorable for competition with other males 
by increasing embryonic growth rate, whereas female gene 
transmission is favorable for maximizing group size of litters, 
in competition with other females. Therefore, IGF-II, which 
is important for growth of the animal, is paternally expressed, 
whereas the type II IGF receptor should suppress growth by 
removing extracellular IGF-II and consequently is maternally 
expressed in order to meet these evolutionary considerations 
(46). 
IGF-II AMD TUMORIGEHESIS 
• IGF-II has been implicated in tumor growth, since its 
production is enhanced in a number of embryonal and adult 
tumors (47,48). It is now generally accepted that most cases of 
the syndrome of non-islet cell tumor hypoglycemia are caused 
by hypersecretion of IGF-II by the tumor. Due to abnormali- 
ties in expression of both IGFBP-3 and its acid-labile subunit, 
the elevation of free IGF-II in serum leads to an increased 
bioactiviry, explaining the marked hypoglycaemia of these 
patients (49). 
IGF-II is not only involved in controlling the proliferation of 
previously transformed cells but also in the transformation 
process itself. Loss of the genetic imprinting of IGF-II occur- 
ring in adult-onset malignancy as well as in embryonic tu- 
mors results in an increased expression of IGF-II (50,51). Thus, 
alterations in imprinting may prove to be an important epige- 
netic mechanism for the formation or maintenance of neo- 
plasms throughout life. In this respect, it has been demon- 
strated that transgenic mice, in which expression of IGF-II 
was targeted to the mammary gland by placing it under con- 
trol of the sheep 6-lactoglobulin promoter, develop an excess 
of mammary tumors (52). In addition, transgenic mice in which 
IGF-II expression was targeted to the liver develop a variety 
of tumors with a preponderance of hepatocellular carcinomas 
(38). These studies are the first in vivo experiments to suggest 
a direct role for IGF-II in the malignant transformation of 
cells 
With respect to the development of metastases, proliferation 
and cell motility are required. Tumorigenesis and metastatic 
progression seem to be independent events. The mitogenic sig- 
nal of IGF-II is mediated by the type I IGF receptor, whereas 
locomotion acts by the type n IGF receptor, as shown in rhabdo- 
myosarcoma cells (47). Thus, although expression of IGF-II 
is important in tumorigenesis, the type I IGF receptor is one 
of the most promising targets for effective antimetastatic 
therapy. This receptor can act as a ligand-dependent oncogene 
(53,54). Evidence comes from studies with rat glioblastoma 
cells which are IGF-I receptor-deficient. When injected into 
rats these cells are unable to form tumors in contrast with the 
wild-type cells, which grow into large tumors (55). These and 
other results suggest that type I IGF receptors are extremely 
important in establishing and maintaining the transformed 
phenotype as well as in regulating metastases (54). Recently it 
has been demonstrated that C-terminal truncation of the type 
I IGF receptor is essential for transformation but not for 
mitogenesis, thus these two functions can be dissociated at an 
intramolecular level (56). 
IGF-II AND APOPTOSIS 
• Growth of tumors depends not only on cell prolifera- 
tion, but also on the rate of programmed cell death, or apop- 
tosis (57). Autocrine production of IGF-II may support cell 
transformation by either enhancing proliferation or increasing 
resistance to apoptosis. In this regard, it has been shown that 
transgenic mice homozygous for a disruption of the IGF-II gene 
develop tumors with a reduced grade of malignancy and a 
higher incidence of apoptosis (58). In addition, the type I IGF 
receptor protects tumor cells from apoptosis in vivo (59). 
CONCLUSIONS 
• IGF-II is involved in a variety of cellular responses, 
such as proliferation, differentiation, intermediary metabolism, 
migration, and transformation. Although its role in growth 
regulation seems to be well established, several major ques- 
tions still remain, e.g. the function of IGF-II in regeneration 
as well as its interplay with other growth factors. The specific 
  
Biomed Rev 5, 1996 
67 
  
  
role of the high postnatal IGF-II levels in humans and other 
mammals remains puzzling and the question arises as to 
whether IGF-II is merely a regulator of metabolic processes or 
a modulator of IGF-I functions. Furthermore, the cellular 
mechanism responsible for the translation of a specific signal 
into either a metabolic, mitogenic, differentiating or transfor- 
ming response needs elucidation (Fig.l). 
Much work has to be done to better understand the complex 
regulatory mechanisms of IGF-II in the process of growth and 
development. Refinements in the technology of homologous 
recombination by knocking genes "in" instead of "out" can be 
a helpful tool in untangling this complex system (60). In ad- 
dition, non-rodent animal models overexpressing IGF-II will 
be most helpful to find out whether or not IGF-II is of vital 
importance in animals with high concentrations of IGF-II post- 
natally. 
Research in an attempt to unravel the function of IGF-II in the 
cycle of life evolves like a mandala (61): it started many years 
ago and although a circle with increasing diameter has devel- 
oped around this starting point, the final appearance of the 
IGF-II masterpiece is at present still an enigma. 
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